Isatuximab-Pomalidomide-Dexamethasone Versus Pomalidomide-Dexamethasone in East Asian Patients With Relapsed/Refractory Multiple Myeloma: ICARIA-MM Subgroup Analysis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Sunami, Kazutaka | - |
dc.contributor.author | Ikeda, Takashi | - |
dc.contributor.author | Huang, Shang-Yi | - |
dc.contributor.author | Wang, Ming-Chung | - |
dc.contributor.author | Koh, Youngil | - |
dc.contributor.author | Min, Chang Ki | - |
dc.contributor.author | Yeh, Su-Peng | - |
dc.contributor.author | Matsumoto, Morio | - |
dc.contributor.author | Uchiyama, Michihiro | - |
dc.contributor.author | Iyama, Satoshi | - |
dc.contributor.author | Shimazaki, Chihiro | - |
dc.contributor.author | Lee, Jae Hoon | - |
dc.contributor.author | Kim, Kihyun | - |
dc.contributor.author | Kaneko, Hitomi | - |
dc.contributor.author | Kim, Jin Seok | - |
dc.contributor.author | Lin, Tung-Liang | - |
dc.contributor.author | Campana, Frank | - |
dc.contributor.author | Tada, Keisuke | - |
dc.contributor.author | Iida, Shinsuke | - |
dc.contributor.author | Suzuki, Kenshi | - |
dc.date.accessioned | 2022-09-08T03:40:08Z | - |
dc.date.available | 2022-09-08T03:40:08Z | - |
dc.date.created | 2022-09-08 | - |
dc.date.issued | 2022-08 | - |
dc.identifier.issn | 2152-2650 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/85436 | - |
dc.description.abstract | Data from the phase III ICARIA-MM study in patients with relapsed/refractory multiple myeloma demonstrated significant improvements in progression-free survival and response rates with isatuximab plus pomalidomide and dexamethasone (Isa-Pd) versus pomalidomide and dexamethasone. This predefined subgroup analysis confirmed the efficacy and safety of Isa-Pd in Japanese, Korean, and Taiwanese patients, supporting the use of this treatment combination in East Asia. Background: In the pivotal phase III, randomized, multicenter ICARIA-MM study (NCT02990338), isatuximab plus pomalidomide and dexamethasone (Isa-Pd) improved progression-free survival and overall response rate versus pomalidomide and dexamethasone (Pd) in the overall population of patients with relapsed/refractory multiple myeloma. Patients and Methods: In this predefined subgroup analysis, efficacy, and safety between East Asian patients and the overall population were assessed. Results: In total, 36 East Asian patients were included (Japanese, n = 13; Korean, n = 9; Taiwanese, n = 14). At a median follow-up of 11.6 months, median progression-free survival was not reached (95% confidence interval [CI] 5.80-not calculable) in the Isa-Pd arm and was 7.9 months (95% CI 2.90-not calculable) in the Pd arm. The hazard ratio for the between-group difference was 0.52 (95% CI 0.19-1.39), which was similar to the overall population (hazard ratio, 0.60; 95% CI 0.44-0.82). No new safety signals were observed, except that a higher proportion of patients in the East Asian population experienced Grade >= 3 neutropenia compared with the overall population. Conclusion: These results confirm the efficacy of Isa-Pd in East Asian patients with relapsed/refractory multiple myeloma, and the related safety data are consistent with those observed in the overall population and are manageable. (C) 2022 The Author(s). Published by Elsevier Inc. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | CIG MEDIA GROUP, LP | - |
dc.relation.isPartOf | CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | - |
dc.title | Isatuximab-Pomalidomide-Dexamethasone Versus Pomalidomide-Dexamethasone in East Asian Patients With Relapsed/Refractory Multiple Myeloma: ICARIA-MM Subgroup Analysis | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000834076800010 | - |
dc.identifier.doi | 10.1016/j.clml.2022.04.005 | - |
dc.identifier.bibliographicCitation | CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, v.22, no.8, pp.E751 - E761 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-85131126183 | - |
dc.citation.endPage | E761 | - |
dc.citation.startPage | E751 | - |
dc.citation.title | CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | - |
dc.citation.volume | 22 | - |
dc.citation.number | 8 | - |
dc.contributor.affiliatedAuthor | Lee, Jae Hoon | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Efficacy and safety | - |
dc.subject.keywordAuthor | Far East | - |
dc.subject.keywordAuthor | Isa-Pd | - |
dc.subject.keywordAuthor | Japan | - |
dc.subject.keywordAuthor | RRMM | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | LENALIDOMIDE | - |
dc.subject.keywordPlus | EPIDEMIOLOGY | - |
dc.subject.keywordPlus | DARATUMUMAB | - |
dc.subject.keywordPlus | BORTEZOMIB | - |
dc.subject.keywordPlus | ELOTUZUMAB | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | TAIWAN | - |
dc.subject.keywordPlus | RISK | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Hematology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Hematology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.